信必可联合辛伐他汀治疗COPD的效果及对患者肺功能的影响

Effects of Symbicort Combined with Simvastatin in Treatment of COPD and Its Influence on Lung Function of Patients

目的:探究信必可联合辛伐他汀治疗慢性阻塞性肺疾病(COPD)的效果及对患者肺功能的影响.方法:选取2015年8月-2018年8月笔者所在医院收治的162例COPD患者为受试对象,使用随机数字表法分为联合组与对照组,各81例.对照组予以常规药物及信必可,联合组在对照组基础上给予辛伐他汀.比较两组治疗前及治疗3个月后血清炎性因子[超敏C-反应蛋白(hs-CRP)、降钙素原(PCT)]、动脉血气[氧分压(PaO2)、二氧化碳分压(PaCO2)]、肺功能[第1秒用力呼气容积(FEV1)、用力肺活量(FVC)]水平变化,并比较治疗期间两组不良反应发生情况.结果:治疗后两组PaO2、FEV1、FVC水平均高于治疗前,且联合组各指标均高于对照组,差异均有统计学意义(P<0.05);治疗后两组PCT、hs-CRP、PaCO2水平均低于治疗前,且联合组各指标均低于对照组,差异均有统计学意义(P<0.05);治疗期间两组不良反应发生率比较差异无统计学意义(P>0.05).结论:信必可联合辛伐他汀治疗COPD的效果显著,可降低炎性因子水平,改善患者动脉血气和肺功能,不良反应较少.

Objective:To explore the effects of Symbicort combined with Simvastatin in treatment of chronic obstructive pulmonary disease(COPD)and its influence on lung function of patients.Method:A total of 162 patients with COPD who were admitted to our hospital from August 2015 to August 2018 were selected as the subjects.They were divided into the combined group and the control group by random number table method,with 81 cases in each group.The control group was given conventional drugs and Symbicort,and the combined group was given Simvastatin on the basis of the control group.The serum inflammatory factors[high-sensitivity C-reactive protein(hs-CRP),procalcitonin(PCT)],arterial blood gas[partial pressure of oxygen(PaO2),partial pressure of carbon dioxide(PaCO2)]and lung function[forced expiratory volume in 1 second(FEV1),forced vital capacity(FVC)]were compared between the two groups before treatment and after 3 months of treatment,and the occurrence of adverse reactions during treatment were compared between the two groups.Result:The PaO2,FEV1,FVC level of the two groups after treatment was higher than that before treatment,and the indexes of the combined group were higher than those of the control group,the differences were statistically significant(P<0.05).The PCT,hs-CRP,PaCO2 levels of the two groups after treatment were lower than before treatment,and the indexes of the combined group were lower than those of the control group,the differences were statistically significant(P<0.05).There was no significant difference in adverse reactions between the two groups during treatment(P>0.05).Conclusion:Symbicort combined with Simvastatin has a significant effect on COPD.It can reduce the levels of inflammatory factors,and improve arterial blood gas and lung function,and has fewer adverse reactions.